Data / Drug companies / Baxter Healthcare Corporation
Baxter Healthcare Corporation: 37 products in the FDA NDC directory, labeler code 36000
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Baxter Healthcare Corporation (labeler code 36000) lists 37 products in the FDA National Drug Code Directory, covering 21 finished drugs by generic name. By type: 37 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on November 3, 2026.
The request: Watch Baxter Healthcare Corporation (FDA labeler code 36000): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 36000
- Products in commercial distribution
- 37
- Packages
- 42
- Finished drugs by generic name
- 21
- Prescription products
- 37
- Over the counter products
- 0
- Flagged as original packager
- 35 of 35 products that carry the flag
- Started marketing in the last 12 months
- 9
- Earliest marketing start
- September 25, 2012
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 37 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 37 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Furosemide | 6 | 63 |
| Levetiracetam | 4 | 87 |
| Phenylephrine hydrochloride | 3 | 77 |
| Labetalol hydrochloride | 3 | 43 |
| Acetaminophen | 2 | 214 |
| Naloxone hydrochloride | 2 | 40 |
| Flumazenil | 2 | 8 |
| Tobramycin | 2 | 41 |
| Propofol | 1 | 15 |
| Sumatriptan | 1 | 28 |
| Levofloxacin | 1 | 42 |
| Regadenoson | 1 | 14 |
| Dihydroergotamine mesylate | 1 | 13 |
| Levocarnitine | 1 | 10 |
| Ondansetron hydrochloride | 1 | 48 |
| Dexmedetomidine hydrochloride | 1 | 21 |
| Palonosetron hydrochloride | 1 | 11 |
| Ephedrine sulfate | 1 | 26 |
| Metoclopramide | 1 | 30 |
| Metoprolol tartrate | 1 | 46 |
| Methocarbamol | 1 | 67 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Injection, solution | 18 | 48.6% |
| Injection | 15 | 40.5% |
| Injection, solution, concentrate | 2 | 5.4% |
| Injection, emulsion | 1 | 2.7% |
| Solution | 1 | 2.7% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Propofol | 36000-058 | Injection, emulsion | Generic drugs (ANDA) | November 3, 2026 |
| Metoclopramide | 36000-366 | Injection, solution | Generic drugs (ANDA) | September 11, 2026 |
| Levetiracetam | 36000-265 | Injection, solution, concentrate | Generic drugs (ANDA) | August 6, 2026 |
| Ephedrine sulfate | 36000-336 | Injection | Generic drugs (ANDA) | July 8, 2026 |
| Levocarnitine | 36000-368 | Injection, solution | Generic drugs (ANDA) | July 2, 2026 |
| Dexmedetomidine Hydrochloride | 36000-262 | Injection, solution, concentrate | Generic drugs (ANDA) | April 16, 2026 |
| Phenylephrine hydrochloride | 36000-362 | Injection | Generic drugs (ANDA) | April 6, 2026 |
| Phenylephrine hydrochloride | 36000-360 | Injection | Generic drugs (ANDA) | April 6, 2026 |
| Phenylephrine hydrochloride | 36000-358 | Injection | Generic drugs (ANDA) | April 6, 2026 |
| Acetaminophen | 36000-372 | Injection, solution | Generic drugs (ANDA) | May 21, 2025 |
| Dihydroergotamine mesylate | 36000-300 | Injection, solution | Generic drugs (ANDA) | January 7, 2025 |
| Levetiracetam | 36000-356 | Injection | Generic drugs (ANDA) | October 2, 2023 |
| Levetiracetam | 36000-354 | Injection | Generic drugs (ANDA) | October 2, 2023 |
| Levetiracetam | 36000-352 | Injection | Generic drugs (ANDA) | October 2, 2023 |
| Regadenoson | 36000-364 | Injection, solution | Generic drugs (ANDA) | May 23, 2023 |
| Sumatriptan | 36000-289 | Injection | Generic drugs (ANDA) | January 19, 2023 |
| Naloxone hydrochloride | 36000-310 | Injection, solution | Generic drugs (ANDA) | November 7, 2022 |
| Methocarbamol | 36000-302 | Injection | Generic drugs (ANDA) | July 14, 2022 |
| Palonosetron Hydrochloride | 36000-326 | Injection | Generic drugs (ANDA) | November 12, 2021 |
| Acetaminophen | 36000-306 | Injection, solution | Generic drugs (ANDA) | September 17, 2021 |
| Naloxone hydrochloride | 36000-308 | Injection, solution | Generic drugs (ANDA) | January 29, 2021 |
| Labetalol Hydrochloride | 36000-324 | Injection, solution | Generic drugs (ANDA) | January 26, 2021 |
| Labetalol Hydrochloride | 36000-322 | Injection, solution | Generic drugs (ANDA) | January 26, 2021 |
| Labetalol Hydrochloride | 36000-320 | Injection, solution | Generic drugs (ANDA) | January 26, 2021 |
| Flumazenil | 36000-149 | Injection | Generic drugs (ANDA) | October 1, 2017 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.